Laboratory Evaluation of a Dual-Path Platform Assay for Rapid Point-of-Care HIV and Syphilis Testing

dc.date.accessioned2019-02-06T14:52:38Z
dc.date.available2019-02-06T14:52:38Z
dc.date.created2019-02-06T14:52:38Z
dc.date.issued2016
dc.identifierhttps://hdl.handle.net/20.500.12866/5340
dc.identifierhttps://doi.org/10.1128/JCM.03152-15
dc.description.abstractWe assessed the laboratory performance of the Chembio dual-path platform HIV-syphilis rapid immunodiagnostic test and electronic reader for detection of HIV and Treponema pallidum antibodies in 450 previously characterized serum specimens. For visual or electronic reader HIV antibody detection, the sensitivity was 100% and the specificity was 98.7%. For visual T. pallidum antibody detection, the test sensitivity was 94.7% and the specificity was 100.0%; with the electronic reader, the sensitivity was 94.7% and the specificity was 99.7%.
dc.languageeng
dc.publisherAmerican Society for Microbiology
dc.relationJournal of Clinical Microbiology
dc.relation1098-660X
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectHumans
dc.subjectSensitivity and Specificity
dc.subjectReproducibility of Results
dc.subjectPoint-of-Care Systems
dc.subjectHIV Infections/diagnosis
dc.subjectSyphilis/diagnosis
dc.subjectCoinfection
dc.subjectImmunologic Tests/methods/standards
dc.subjectAntigens, Bacterial/immunology
dc.subjectHIV Antibodies/immunology
dc.subjectHIV Core Protein p24/immunology
dc.titleLaboratory Evaluation of a Dual-Path Platform Assay for Rapid Point-of-Care HIV and Syphilis Testing
dc.typeinfo:eu-repo/semantics/article


Este ítem pertenece a la siguiente institución